Company News: Molecular Health Strengthens U.S. Based Executive Management Team


– Appoints Gerry Sheridan as Chief Financial Officer

– Appoints Dr. Les Paul as Chief Medical Officer

Molecular Health, a leader in precision medicine technology focused on commercializing products utilizing its proprietary Dataome™ technology platform, today announced it has strengthened its leadership team with the appointment of two U.S.-based executives. Gerry Sheridan will serve as Chief Financial Officer and Dr. Les Paul as Chief Medical Officer. Mr. Sheridan and Dr. Paul will be based in the Company’s U.S. headquarters in Boston to facilitate the Company’s expansion into the U.S. commercial markets and building of an expanded U.S. operational infrastructure.

Molecular Health Executive Chairman Friedrich von Bohlen commented, “The addition of Gerry and Les to our executive team is an exciting and critical step in building our U.S. commercial and operational infrastructure to support the continued commercial ramp of the GUIDE platform. Both bring substantial experience from commercial stage healthcare and oncology-focused companies. Their combined financial, medical and operational expertise together with their longstanding relationships with stakeholders across the U.S., make both Gerry and Les the optimal candidates to help deliver GUIDE, our fully automated cloud-based clinical decision support software, to the growing U.S. market.”

Mr. Sheridan said, “It is a tremendous opportunity to join Molecular Health at this juncture in their corporate development. Their existing global footprint, growth potential and commitment to bringing their revolutionary technology to such a large healthcare constituency make it an exciting time to join such a dynamic team. ”

Dr. Paul added, “GUIDE is uniquely positioned to systematically lead physicians and their patients to the best possible treatment outcomes.  Information sciences as a support tool to help drive informed treatment decisions based upon the latest and most relevant literature, discoveries and knowledge is a tremendous offering to the medical community.  I feel privileged to join the Molecular Health team and am excited to help broaden the market adoption of this technology. I am confident it will make a lasting impact on patients’ lives.”

Mr. Sheridan brings to Molecular Health over 25 years of international financial, operating and consulting experience and extensive knowledge of U.S. and European markets. Most recently, Gerry served as CFO of Seno Medical Instruments, an oncologic medical device company, where he led their most recent Series C funding round of $80 Million as the company began marketing and commercializing its device. Prior to his experience at Seno, Gerry was CFO of GDC Technics, an aerospace design firm. Mr. Sheridan graduated from University College Dublin in Ireland, is a qualified Chartered Accountant, a Certified Public Accountant and a member of the American Institute of Certified Public Accountants.

Dr. Paul joins Molecular Health following a lengthy career in medicine and in business. He has served as Chief Medical Officer at Caris Life Sciences; SVP, Global Medical Affairs at Intermune, VP, U.S. Medical Affairs at Novartis, VP, U.S. Medical Affairs at AstraZeneca R&D, VP, Medical Policy / Programs and Medical Affairs at MedCo Health Solutions before it was acquired by Express Scripts in 2012, and most recently he served as Principal at Tradewind Life Science Advisors. He has extensive experience in the pharmaceutical industry and in leading integrated U.S. and Global Medical Affairs teams in multiple therapeutic areas including precision cancer therapy and diagnostics. He has also been responsible for the medical aspects of product commercialization, medical policy, publications and scientific communication, and research.  Dr. Paul received his Doctor of Medicine Degree from the University of Illinois and his Masters in Preventative Medicine and Administrative Medicine from the University of Wisconsin-Madison. He is also Board Certified in Internal Medicine & Pulmonary Disease from the American Board of Internal Medicine.